X

ABBV Infographic: AbbVie’s Q1 2023 earnings and revenue decline

Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) reported a decrease in first-quarter 2023 adjusted earnings and revenues. The company also provided guidance for fiscal 2023.

Total revenues decreased 9.7% year-over-year to $12.23 billion, reflecting weakness in the main operating segments.

At $2.46 per share, adjusted net income was lower than the $3.16 per share reported in the prior-year period. First-quarter unadjusted profit dropped to $239 million or $0.13 per share from $4.49 billion or $2.51 per share in the first quarter of 2022.

“This year is off to an excellent start, with first-quarter revenues and EPS ahead of our expectations, driven by strong commercial execution across all areas of our diversified portfolio,” said Richard A. Gonzalez, CEO of AbbVie.

Prior Performance

Related Post